---
title: "Opdivo (nivolumab) in metastatic non-small cell lung cancer: Access and coverage questions"
description: "Access and coverage questions on Opdivo (nivolumab) in metastatic non-small cell lung cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Cost and coverage, Access support, Patient support, and Access and support. Questions: Is there an Opdivo copay assistance program? Does BMS help with Opdivo prior authorization and appeals? What access and copay support does BMS offer for Opdivo Qvantig? Is there a patient support program for people prescribed Opdivo? 3 further questions follow. 7 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/access-and-coverage"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab) in metastatic non-small cell lung cancer: Access and coverage questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)

Questions that apply to every indication of Opdivo are on [Opdivo (nivolumab), all indications](https://www.evicenter.com/medical-information/opdivo).

## Cost and coverage

<a id="opdivo-copay-assistance"></a>

### Is there an Opdivo copay assistance program?

> “The BMS Access Support Co-Pay Assistance Program assists with out-of-pocket co-payment or co-insurance requirements
> for eligible, commercially-insured patients who have been prescribed certain BMS products, including OPDIVO Qvantig®, OPDIVO® IV, and OPDIVO + YERVOY® (ipilimumab).”

Source: [OPDIVO: Patient Access, captured 2026-11-13](https://www.opdivohcp.com/resources/patient-access-support#:~:text=The%20BMS%20Access%20Support%20Co%2DPay,and%20OPDIVO%20%2B%20YERVOY%C2%AE%20%28ipilimumab%29.)

## Access support

<a id="opdivo-access-support"></a>

### Does BMS help with Opdivo prior authorization and appeals?

> “The BMS Access Support program is dedicated to helping patients access their prescribed BMS medications. We may offer benefits investigations, prior authorization assistance, appeals process support, and information on financial support options.”

Source: [OPDIVO: Patient Access, captured 2026-11-13](https://www.opdivohcp.com/resources/patient-access-support#:~:text=The%20BMS%20Access%20Support%20program,information%20on%20financial%20support%20options.)

> “To learn more, visit www.BMSAccessSupport.com, or call BMS Access Support at 1-800-861-0048, 8 am to 8 pm ET, Monday – Friday.”

Source: [OPDIVO: Patient Access, captured 2026-11-13](https://www.opdivohcp.com/resources/patient-access-support#:~:text=To%20learn%20more%2C%20visit%20www.BMSAccessSupport.com%2C,pm%20ET%2C%20Monday%20%E2%80%93%20Friday.)

<a id="opdivo-qvantig-access-support"></a>

### What access and copay support does BMS offer for Opdivo Qvantig?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “BMS Access Support® offers benefit investigation, prior authorization assistance, and appeal process support, as well as an easy-to-initiate co-pay assistance process and information on financial support.
>
> The Oncology Co-Pay Assistance Program assists with out-of-pocket co-payment or co-insurance requirements for eligible, commercially insured patients who have been prescribed certain Bristol Myers Squibb oncology products, including OPDIVO Qvantig.”

Source: [OPDIVO: FAQ's, captured 2026-11-13](https://www.opdivohcp.com/qvantig/faq#:~:text=BMS%20Access%20Support%C2%AE%20offers%20benefit,oncology%20products%2C%20including%20OPDIVO%20Qvantig.)

On the page, select: Are there any other support programs for patients about treatment with OPDIVO Qvantig?

## Patient support

<a id="opdivo-patient-support"></a>

### Is there a patient support program for people prescribed Opdivo?

> “A complimentary program for patients that includes helpful resources and information about support and advocacy groups, and provides access to a personal care counselor for patients who have been prescribed OPDIVO IV or OPDIVO Qvantig.”

Source: [OPDIVO: Patient Access, captured 2026-11-13](https://www.opdivohcp.com/resources/patient-access-support#:~:text=A%20complimentary%20program%20for%20patients,OPDIVO%20IV%20or%20OPDIVO%20Qvantig.)

> “If your patients have any general questions about OPDIVO Qvantig, they can call 1-855-OPDIVO-1 (1-855-673-4861) 8 AM to 8 PM ET, Monday through Friday. Patients can enroll at www.opdivo.com/opdivo-with-you-sign-up.”

Source: [OPDIVO: FAQ's, captured 2026-11-13](https://www.opdivohcp.com/qvantig/faq#:~:text=If%20your%20patients%20have%20any,Patients%20can%20enroll%20at%20www.opdivo.com%2Fopdivo%2Dwith%2Dyou%2Dsign%2Dup.)

On the page, select: Are there any other support programs for patients about treatment with OPDIVO Qvantig?

## Access and support

<a id="opdivo-qvantig-practice-support"></a>

### What training does BMS offer practices starting Opdivo Qvantig?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “Contact your BMS sales representative for resources for our OPDIVO Qvantig program including:
>
> Administration training/demonstrations, if helpful
> Storage specifications, and preparation, safety, and patient-care protocols
> Inventory management support
> Nursing education
> Other instructive resources”

Source: [OPDIVO: Support, captured 2026-11-13](https://www.opdivohcp.com/qvantig/support#:~:text=Contact%20your%20BMS%20sales%20representative,Other%20instructive%20resources)

<a id="opdivo-bms-connect"></a>

### What is BMS Connect for Opdivo Qvantig?

Applies to: Metastatic NSCLC in adults with progression on or after platinum-based chemotherapy: OPDIVO QVANTIG monotherapy

> “BMS Connect provides healthcare professionals a central source of useful information about therapies from Bristol Myers Squibb, including OPDIVO Qvantig, and help for appropriate patients to get access to reimbursement support. Find links to the full prescribing information, medication guide, and pricing information.”

Source: [OPDIVO: FAQ's, captured 2026-11-13](https://www.opdivohcp.com/qvantig/faq#:~:text=BMS%20Connect%20provides%20healthcare%20professionals,medication%20guide%2C%20and%20pricing%20information.)

On the page, select: What is BMS Connect?

<a id="opdivo-medical-information"></a>

### How can prescribers contact Opdivo medical information?

> “Visit BMSmedinfo.com or call 1-800-721-5072. Report side effects to the FDA at 1-800-332-1088.”

Source: [OPDIVO: Support & Resources, captured 2026-11-13](https://www.opdivohcp.com/resources#:~:text=Visit%20BMSmedinfo.com%20or%20call%201%2D800%2D721%2D5072.,to%20the%20FDA%20at%201%2D800%2D332%2D1088.)

## Related pages
- [Medical information: Opdivo (nivolumab): Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)
- [Indication](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/guidelines)
